Gilead Sciences, Inc. (GILD) Insider Sells $5,509,508.29 in Stock
Gilead Sciences, Inc. (NASDAQ:GILD) insider John C. Martin sold 73,333 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the transaction, the insider now owns 3,070,099 shares of the company’s stock, valued at approximately $230,656,537.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) traded down $1.15 during trading on Friday, hitting $73.81. 7,376,747 shares of the stock traded hands, compared to its average volume of 8,814,002. The stock has a market cap of $96.47 billion, a P/E ratio of 7.70 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter last year, the business earned $2.75 earnings per share. The business’s revenue was down 13.2% on a year-over-year basis. sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is 23.69%.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/03/gilead-sciences-inc-gild-insider-sells-5509508-29-in-stock.html.
Several institutional investors have recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares during the period. Penserra Capital Management LLC lifted its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares during the period. American Beacon Advisors Inc. purchased a new stake in Gilead Sciences in the first quarter worth $143,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Gilead Sciences in the second quarter worth $147,000. Finally, Hanson & Doremus Investment Management lifted its stake in Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the period. Hedge funds and other institutional investors own 74.28% of the company’s stock.
Several equities research analysts have commented on the stock. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. Vetr downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective on the stock. in a report on Monday, September 4th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and a consensus price target of $85.68.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.